Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease treatments, has announced its participation in Canaccord Genuity's 45th Annual Growth Conference. The company's CEO, John P. Butler, will engage in a Fireside Chat on Wednesday, August 13 at 1:30 PM EDT.
The conference is scheduled for August 12-14, 2025 in Boston. Investors can access the presentation webcast through the Investors section of Akebia's website after the conference.
Akebia Therapeutics (Nasdaq: AKBA), un'azienda biofarmaceutica specializzata in trattamenti per le malattie renali, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Crescita di Canaccord Genuity. Il CEO dell'azienda, John P. Butler, parteciperà a una Fireside Chat mercoledì 13 agosto alle 13:30 EDT.
La conferenza si terrà dal 12 al 14 agosto 2025 a Boston. Gli investitori potranno accedere alla presentazione in webcast tramite la sezione Investor del sito web di Akebia dopo la conferenza.
Akebia Therapeutics (Nasdaq: AKBA), una empresa biofarmacéutica centrada en tratamientos para enfermedades renales, ha anunciado su participación en la 45ª Conferencia Anual de Crecimiento de Canaccord Genuity. El CEO de la compañía, John P. Butler, participará en una Fireside Chat el miércoles 13 de agosto a la 1:30 PM EDT.
La conferencia está programada del 12 al 14 de agosto de 2025 en Boston. Los inversionistas podrán acceder a la presentación vía webcast a través de la sección de Inversores en el sitio web de Akebia después de la conferencia.
Akebia Therapeutics (나스닥: AKBA)는 신장 질환 치료에 중점을 둔 바이오제약 회사로, Canaccord Genuity의 제45회 연례 성장 컨퍼런스에 참여한다고 발표했습니다. 회사의 CEO인 John P. Butler가 2025년 8월 13일 수요일 오후 1시 30분 EDT에 Fireside Chat에 참여할 예정입니다.
컨퍼런스는 2025년 8월 12일부터 14일까지 보스턴에서 개최됩니다. 투자자들은 컨퍼런스 이후 Akebia 웹사이트의 투자자 섹션을 통해 발표 웹캐스트에 접속할 수 있습니다.
Akebia Therapeutics (Nasdaq : AKBA), une société biopharmaceutique spécialisée dans les traitements des maladies rénales, a annoncé sa participation à la 45e conférence annuelle sur la croissance de Canaccord Genuity. Le PDG de la société, John P. Butler, participera à une discussion informelle le mercredi 13 août à 13h30 EDT.
La conférence se déroulera du 12 au 14 août 2025 à Boston. Les investisseurs pourront accéder à la présentation en webcast via la section Investisseurs du site web d'Akebia après la conférence.
Akebia Therapeutics (Nasdaq: AKBA), ein biopharmazeutisches Unternehmen, das sich auf die Behandlung von Nierenerkrankungen spezialisiert hat, hat seine Teilnahme an der 45. jährlichen Wachstums-Konferenz von Canaccord Genuity angekündigt. Der CEO des Unternehmens, John P. Butler, wird am Mittwoch, den 13. August um 13:30 Uhr EDT an einem Fireside Chat teilnehmen.
Die Konferenz findet vom 12. bis 14. August 2025 in Boston statt. Investoren können die Präsentation nach der Konferenz über den Investor-Bereich auf der Website von Akebia als Webcast abrufen.
- None.
- None.
CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, will participate in a Fireside Chat at Canaccord Genuity’s 45th Annual Growth Conference on Wednesday, August 13 at 1:30 PM EDT. The conference will take place August 12-14, 2025 in Boston.
A webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com following the conference.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
When is Akebia Therapeutics (AKBA) presenting at the Canaccord Genuity Growth Conference 2025?
How can investors access Akebia Therapeutics' (AKBA) Canaccord conference presentation?
Who will represent Akebia Therapeutics (AKBA) at the Canaccord Genuity Conference?
What type of presentation will Akebia Therapeutics (AKBA) give at the Canaccord conference?
